Review
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. May 7, 2008; 14(17): 2691-2701
Published online May 7, 2008. doi: 10.3748/wjg.14.2691
Table 2 Studies on circulating VEGF-C/D in human solid malignancies (clinicopathological association)
TumorMarkerSampleCases (n)LNMPrognostic impactRef.
Gastric cancerVEGF-CSerum80P = 0.001P = 0.00167
Esophageal cancerVEGF-CSerum70P = 0.022ND102
Esophageal cancerVEGF-CSerum73( + )1ND103
Colorectal cancerVEGF-DPlasma59(-)ND38
Colorectal cancerVEGF-CPlasma41( + )2ND144
Colorectal cancerVEGF-CPlasma120(-)ND145
VEGF-D(-)
Colorectal cancerVEGF-CSerum66( + )ND146
Breast cancerVEGF-DPlasma51(-)ND46
Breast cancerVEGF-CPlasma122(-)(-)47
Breast cancer3VEGF-DPlasma14248
Nsc4 lung cancerVEGF-CSerum92P = 0.0260ND49
Nsc lung cancerVEGF-CSerum78P = 0.0004ND50
Nsc lung cancerVEGF-CSerum116P = 0.0007ND51
Cervical cancerVEGF-CSerum78P = 0.0001P = 0.011252
Cervical cancerVEGF-CSerum205( + )2( + )253
Prostate cancerVEGF-DPlasma30P = 0.0043ND54
HNSCC5VEGF-CPlasma46(-)(-)55